UK-headquartered GlaxoSmithKline, the world's second largest drugmaker by sales, has announced plans to dramatically reduce its R&D head count, revealing that a total of about 850 jobs in the sector would go.
GSK, which has around15,000 R&D employees, including 5,000 in the UK across four sites near London and in Hertfordshire, said that jobs would go both at its home base and in the USA. A company spokesman said: "we believe these changes ae necessary as part GSK's longer-term strategy."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze